615 related articles for article (PubMed ID: 11413242)
21. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities.
Sadée W; Wang D; Bilsky EJ
Life Sci; 2005 Feb; 76(13):1427-37. PubMed ID: 15680308
[TBL] [Abstract][Full Text] [Related]
22. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
23. Calmodulin regulation of basal and agonist-stimulated G protein coupling by the mu-opioid receptor (OP(3)) in morphine-pretreated cell.
Wang D; Surratt CK; Sadée W
J Neurochem; 2000 Aug; 75(2):763-71. PubMed ID: 10899953
[TBL] [Abstract][Full Text] [Related]
24. The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity.
Sirohi S; Dighe SV; Madia PA; Yoburn BC
J Pharmacol Exp Ther; 2009 Aug; 330(2):513-9. PubMed ID: 19435929
[TBL] [Abstract][Full Text] [Related]
25. Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.
Melkes B; Hejnova L; Novotny J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1289-1300. PubMed ID: 27600870
[TBL] [Abstract][Full Text] [Related]
26. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
27. Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys.
Li JX; McMahon LR; France CP
Psychopharmacology (Berl); 2008 Jan; 195(4):479-86. PubMed ID: 17874317
[TBL] [Abstract][Full Text] [Related]
28. Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening.
Brillet K; Kieffer BL; Massotte D
BMC Pharmacol; 2003 Dec; 3():14. PubMed ID: 14641935
[TBL] [Abstract][Full Text] [Related]
29. In vivo characterization of the opioid antagonist nalmefene in mice.
Osborn MD; Lowery JJ; Skorput AG; Giuvelis D; Bilsky EJ
Life Sci; 2010 Apr; 86(15-16):624-30. PubMed ID: 20159022
[TBL] [Abstract][Full Text] [Related]
30. Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence.
Walker EA; Sterious SN
Br J Pharmacol; 2005 Aug; 145(7):975-83. PubMed ID: 15912139
[TBL] [Abstract][Full Text] [Related]
31. Increased agonist affinity at the μ-opioid receptor induced by prolonged agonist exposure.
Birdsong WT; Arttamangkul S; Clark MJ; Cheng K; Rice KC; Traynor JR; Williams JT
J Neurosci; 2013 Feb; 33(9):4118-27. PubMed ID: 23447620
[TBL] [Abstract][Full Text] [Related]
32. Pseudoginsenoside-F11 attenuates morphine-induced signalling in Chinese hamster ovary-mu cells.
Li Z; Xu NJ; Wu CF; Xiong Y; Fan HP; Zhang WB; Sun Y; Pei G
Neuroreport; 2001 May; 12(7):1453-6. PubMed ID: 11388428
[TBL] [Abstract][Full Text] [Related]
33. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
34. Involvement of delta 1 and delta 2 opioid receptor subtypes in the development of physical dependence on morphine in mice.
Suzuki T; Tsuji M; Mori T; Misawa M; Nagase H
Pharmacol Biochem Behav; 1997; 57(1-2):293-9. PubMed ID: 9164585
[TBL] [Abstract][Full Text] [Related]
35. G protein activation by endomorphins in the mouse periaqueductal gray matter.
Narita M; Mizoguchi H; Narita M; Dun NJ; Hwang BH; Endoh T; Suzuki T; Nagase H; Suzuki T; Tseng LF
J Biomed Sci; 2000; 7(3):221-5. PubMed ID: 10810240
[TBL] [Abstract][Full Text] [Related]
36. Prohormone convertase 2 (PC2) null mice have increased mu opioid receptor levels accompanied by altered morphine-induced antinociception, tolerance and dependence.
Lutfy K; Parikh D; Lee DL; Liu Y; Ferrini MG; Hamid A; Friedman TC
Neuroscience; 2016 Aug; 329():318-25. PubMed ID: 27208618
[TBL] [Abstract][Full Text] [Related]
37. Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: decrease in activity after chronic morphine treatment.
Selley DE; Nestler EJ; Breivogel CS; Childers SR
Brain Res; 1997 Jan; 746(1-2):10-8. PubMed ID: 9037478
[TBL] [Abstract][Full Text] [Related]
38. Modulation of miR-139-5p on chronic morphine-induced, naloxone-precipitated cAMP overshoot in vitro.
Cao DN; Shi JJ; Wu N; Li J
Metab Brain Dis; 2018 Oct; 33(5):1501-1508. PubMed ID: 29916183
[TBL] [Abstract][Full Text] [Related]
39. Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.
Yuan Y; Li G; He H; Stevens DL; Kozak P; Scoggins KL; Mitra P; Gerk PM; Selley DE; Dewey WL; Zhang Y
ACS Chem Neurosci; 2011 Jul; 2(7):346-51. PubMed ID: 22816021
[TBL] [Abstract][Full Text] [Related]
40. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
Olianas MC; Concas D; Onali P
Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
